EpiVacCorona contains a short fragment of a virus protein and also synthetic peptide antigens. The drug must be administered twice and the process has to be repeated every 3 years.
Ana Popova, head of the Russian National Office for Consumer Protection (Rospotrebnadzor), confirmed that Russia started production of its second vaccine against Covid-19, EpiVacCrona. Subsequently, massive clinical trials with this drug will be developed.
EpiVacCorona is the second Russian vaccine against Covid-19, the first being Sputnik-V, which is currently in the clinical trial phase. According to the authorities, the Russian drugs will have their target audience, therefore, doctors will be able to choose which vaccine to prescribe for different patients.
This Russian vaccine can be produced in large quantities without sharing the same production platform as its predecessor. Popova commented to the media that “he cannot say which is better.”
The Vector Virology and Biotechnology Center is the creator of this drug, which contains a short fragment of a virus protein and also synthetic peptide antigens, which helps increase its safety, according to experts.
The EpiVacCorona indications dictate that the substance must be administered twice and then the process must be repeated every three years.
Russia was the first country in the world to register a vaccine against Covid-19, in a race to stop a pandemic that already has more than 1 million deaths around the planet.
Source: Sputnik – Forbes
Be the first to comment